Picture of Protara Therapeutics logo

TARA Protara Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Annual cashflow statement for Protara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-15-34-47.3-66-40.4
Depreciation
Non-Cash Items0.9569.8413.138.76.66
Unusual Items
Other Non-Cash Items
Changes in Working Capital-1.890.629-0.5160.539-4.14
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Cash from Operating Activities-15.6-23.4-34.5-26.5-37.6
Capital Expenditures-0.016-0.884-0.596-0.12-0.045
Purchase of Fixed Assets
Other Investing Cash Flow Items2.53.72-97.615.153.2
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities2.482.83-98.214.953.1
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities0189-0.228-0.09-0.091
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-13.2169-133-11.615.5